

## Subcutaneous Immunoglobulin (SCIg) Product Dosing

Subcutaneous administration of immunoglobulin can be considered as an alternative to IVIg. The Criteria for Clinical Use of Immunoglobulin in Australia should be referred to for Medical Conditions/Indications that offer this method.

1. If entering an initial authorisation request, complete all of the details as required, until the dosing section is reached. You can follow the instructions on the BloodSTAR – Initial Authorisation Request Tip Sheet.
2. If entering a dose change request, follow the instructions on the BloodSTAR – Product or Dose Change Request until you reach the dose change request details section.

**Please note:** You will need be logged into a hospital participating in the National SCIg program to request 'Subcutaneous' dosing. The facility list is available at <https://www.blood.gov.au/SCIg>.

Additionally, the patient's treating and/or administering facility will need to have a SCIg approved facility listed to request 'Subcutaneous' dosing.

3. Enter the patient's weight. If subcutaneous doses are available for the chosen medical condition/indication, subcutaneous doses will be displayed below the intravenous dose section. Select the required dose by checking the tick box next to the dose name.

The screenshot displays the BloodSTAR dosing interface. At the top, there are input fields for 'Patient Weight' (set to 80.00 kg) and 'Patient Height' (set to cm). A red box highlights the 'Patient Weight' field. To the right, there is a checkbox for 'Use Ideal Body Weight Adjusted Dosing' which is currently unchecked. Below this, a red warning message states: 'Ideal body weight adjusted dosing is not recommended in patients who are: aged less than 18 years; less than 152cm in height; or pregnant. Where the Dose Determining Weight is greater than the patient's actual weight, use the patient's actual weight to calculate the Ig dose.'

The interface is divided into two main sections: 'Intravenous Doses' and 'Subcutaneous Doses'. The 'Subcutaneous Doses' section is highlighted with a red border. Each section contains three options: 'Loading Dose', 'Maintenance Dose', and 'Supplementary Dose', each with a corresponding description.

**Intravenous Doses**

- Loading Dose (IVIg)  
**Description:** One loading dose of 0.4 g/kg in the first month of therapy (in addition to the maintenance dose) is permitted if the serum IgG level is <4 g/L.
- Maintenance Dose (IVIg)  
**Description:** 0.4–0.6g/kg every four weeks or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9 g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1 g/kg may be given over any four week period.
- Supplementary Dose (IVIg)  
**Description:** One additional dose of 0.4g/kg is permitted at any stage (in addition to the maintenance dose) if the serum IgG level is <4g/L.

**Subcutaneous Doses**

- Loading Dose (SCIg)  
**Description:** One loading dose of 0.4 g/kg in the first month of therapy (in addition to the maintenance dose) is permitted if the serum IgG level is <4 g/L.
- Maintenance Dose (SCIg)  
**Description:** 0.1–0.15g/kg every week or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9 g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1 g/kg may be given over any four week period.
- Supplementary Dose (SCIg)  
**Description:** One additional dose of 0.4 g/kg is permitted at any stage (in addition to the maintenance dose) if the serum IgG level is <4g/L.

4. Select the *Preferred Product*, *Dose / Kg*, *Frequency* and *Date Required* for the first dose.

Maintenance Dose (SCIg)

**Description:** 0.1-0.15g/kg every week or more frequently, to achieve IgG trough level of at least the lower limit of the age-specific serum IgG reference range. More frequent dosing to achieve IgG trough level of up to 9g/L is permitted if chronic suppurative lung disease is not adequately controlled at an IgG trough level at the lower limit of the age-specific serum IgG reference range. A total dose of up to 1g/kg may be given over any four week period.

**Infusion Method \*** Subcutaneous

**Preferred Product \***

**Dose / Kg \*** 0.10 g **Total Dose \*** 8.00 g  
The total dose will be rounded to g.

**Frequency \*** Every 2 Weeks for course(s)

**Date Required \***  **Approximate End Date**

Dose will be administered as a divided dose

**Comments**

This dose is also available as intravenous immunoglobulin.

5. As the SCIg dose controlling has not been set in BloodSTAR system, you may be presented with a system alert message, advising you that the dose and/or frequency you have selected is outside what has been set out in the criteria for use. You will need to provide a reason in the free text *Reason* field provided e.g. "SCIg dosing requirements"

**Frequency \*** Every 1 Weeks

**Date Required \*** 29-Jul-2016

**Reason: \***  
SCIg dosing requirements

6. Once all required details have been entered, confirm your contact details and tick the box to indicate all information submitted is true and accurate to the best of your knowledge and then click *Submit*.
7. Your request will be submitted to the Australian Red Cross Lifeblood authorisers for assessment. You will receive an email and an in-system notification when the request has been actioned.